LEXICON SUCCESSFULLY COMPLETES PAHSE I STUDY OF LX1031.
Lexicon Pharmaceuticals' Drug Candidate for Irritable Bowel
Syndrome Completes Phase 1 Clinical Trial Showing Positive Results
Phase 2 Proof-of-Concept Clinical Trial in IBS Patients to . . .
DISCOVERY LABS KL-4 DATA PUBLISHED IN PEDIATRIC RESEARCH.
Discovery Laboratories, Inc. (Nasdaq:DSCO), Warrington, Pa., has
announced the publication in Pediatric Research of data from a
pre-clinical research study conducted at the Nemours Research . . .
PHARMACOPEIA EARNS MILESTONE PAYMENT FROM WYETH.
Pharmacopeia (Nasdaq:PCOP), Princeton, N.J. an innovator in the
discovery and development of novel small molecule therapeutics, has
announced that it has received a milestone payment from . . .
ANTIDEPRESSANTS/COCAINE INTERACT WITH BRAIN CELL TARGETS.
In a first, scientists from Weill Cornell Medical College and
Columbia University Medical Center have described the specifics of how
brain cells process antidepressant drugs, cocaine and . . .
APP PHARMACEUTICALS GETS APPROVALS FOR ADDITIONAL
DOSAGES.
APP Pharmaceuticals, Inc. (Nasdaq:APPX), Schaumburg, Ill., a
leading manufacturer of multi-source and branded injectable
pharmaceutical products, has received final approvals from the U.S. Food
and . . .
REGENERX COMPLETES ENROLLMENT OF PHASE IA FOR HEART DRUG.
RegeneRx Biopharmaceuticals, Bethesda, Md., (AMEX:RGN) has
completed enrollment and dosing of 40 healthy subjects for its Phase IA
clinical trial testing RGN-352, an injectable formulation of T?4 . . .
SENESCO CHOOSES VGXI TO PRODUCE FACTOR 5A PLASMID.
Senesco Technologies, Inc., (AMEX:SNT), Brunswwick, N.J., has
contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to
supply the plasmid portion of the company's combination therapy
consisting . . .
HANA BIOSCIENCES GETS U.S.ORPHAN DRUG DESIGNATION FOR
MARQIBO.
Hana Biosciences (Nasdaq:HNAB), South San Francisco, Calif., a
biopharmaceutical company focused on strengthening the foundation of
cancer care, has announced that the U.S. Food and Drug . . .
BAYER EXPANDS HEMOPHILIA PORTFOLIO FEATURING MAXY-VII.(Company
overview)
Bayer HealthCare is expanding its commitment to hemophilia with the
acquisition of Maxygen's hemophilia program assets, including a
next-generation recombinant Factor VIIa protein known as . . .
OXIGENE BEGINS PHASE II NSCLC TRIAL OF ZYBRESTAT WITH
CHEMOTHERAPY.
OXiGENE, Inc., Waltham, Mass., a clinical-stage biopharmaceutical
company developing novel therapeutics to treat cancer and eye diseases,
announced that the company has begun dosing patients in a . . .
THE GI COMPANY TO PRESENT PHASE II ORAL MUCOSITIS DATA AT
ASCO.
The GI Company, Inc., Framingham, Mass., a privately held developer
of gastrointestinal therapeutics, has announced that an abstract
detailing results from a Phase II clinical trial (2006 - ITF - . . .
WEILL CORNELL INDENTIFIES NEW FORM OF INHERITED CANCER
RISK.
Like the subtext of a novel, the human genome sequence harbors more
information than appears just in its "letters" of A, C, T and
G. Since DNA is a data-packed molecule passed from generation . . .
IMMUNEREGEN/DELSITE COLLABORATE ON NEW FLU TREATMENT.
ImmuneRegen(r) BioSciences, Inc., Scottsdale, Ariz., a wholly owned
biotechnology product development and licensing subsidiary of IR
BioSciences Holdings, Inc. (OTCBB:IRBO), has commenced a . . .
ADOLOR SUBMITS ADL5747 IND FOR DELTA OPIOID RECEPTOR
TARGET.
Adolor Corporation, Exton, Pa., (Nasdaq:ADLR) has announced that
clinical testing will be permitted under an Investigational New Drug
Application (IND) for ADL5747, a novel oral compound that . . .
FDA GIVES TENTATIVE APPROVAL OF STAVZOR.
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN), Miami, Fla., announced
that the U.S. Food and Drug Administration (FDA) has issued a tentative
approval letter related to the New Drug Application (NDA) . . .
NEW DRUG FIGHTS BACTERIAL INFECTIONS IN NOVEL WAY.
Over the course of the 20th Century, doctors waged war against
infectious bacterial illness with the best new weapon they had:
antibiotics.
But the emergence of dangerous, multi-drug resistant . . .
POSITIVE PRECLINICAL RESULTS FROM TOPICAL ZYBRESTAT.
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), Waltham, Mass., a
clinical-stage, biopharmaceutical company developing novel therapeutics
to treat cancer and eye diseases, has reported positive results . . .
UCB FILES NDA FOR LACOSAMIDE FOR DIABETIC NEUROPATHIC
PAIN.
UCB has announced that the FDA has accepted for filing the New Drug
Application (NDA) for the use of lacosamide in the treatment of diabetic
neuropathic pain. The application relates to the tablet . . .
OSTEOPOROSIS: AN EQUAL OPORTUNITY ILLNESS.
Osteoporosis is traditionally thought of as a women's disease,
however, it also poses a significant threat to men. According to the
National Osteoporosis Foundation, twelve million men are at risk . . .
BREAKTHROUGH FOR CANCER PAIN.
Not every breakthrough is positive. Of the approximately 1.4
million new cancer patients in the U.S. each year, more than half
experience pain associated with their disease. The patient's level
of . . .
|
|